These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 20010156)

  • 1. C-reactive protein and cardiovascular diseases--is it ready for primetime?
    Lavie CJ; Milani RV; Verma A; O'Keefe JH
    Am J Med Sci; 2009 Dec; 338(6):486-92. PubMed ID: 20010156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
    Ray KK; Cannon CP; Cairns R; Morrow DA; Rifai N; Kirtane AJ; McCabe CH; Skene AM; Gibson CM; Ridker PM; Braunwald E;
    J Am Coll Cardiol; 2005 Oct; 46(8):1417-24. PubMed ID: 16226164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of C-reactive protein is not associated with reduced cardiovascular risk and mortality in patients treated with statins. A meta-analysis of 22 randomized trials.
    Savarese G; Rosano GM; Parente A; D'Amore C; Reiner MF; Camici GG; Trimarco B; Perrone-Filardi P
    Int J Cardiol; 2014 Nov; 177(1):152-60. PubMed ID: 25499365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
    Kones R
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):309-15. PubMed ID: 19460829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of C-reactive protein when prescribing a statin.
    Kinlay S
    Curr Atheroscler Rep; 2012 Feb; 14(1):26-32. PubMed ID: 22125118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
    Sattar N; Murray HM; McConnachie A; Blauw GJ; Bollen EL; Buckley BM; Cobbe SM; Ford I; Gaw A; Hyland M; Jukema JW; Kamper AM; Macfarlane PW; Murphy MB; Packard CJ; Perry IJ; Stott DJ; Sweeney BJ; Twomey C; Westendorp RG; Shepherd J;
    Circulation; 2007 Feb; 115(8):981-9. PubMed ID: 17283264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On-treatment C-reactive protein and HDL cholesterol levels in patients at intermediate cardiovascular risk: impact on carotid intima-media thickness.
    Pirro M; Vaudo G; Lupattelli G; Pasqualini L; Mannarino MR; Schillaci G; Alaeddin A; Paciullo F; Fallarino F; Bagaglia F; Mannarino E
    Life Sci; 2013 Sep; 93(8):338-43. PubMed ID: 23871987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of antidiabetic and antihyperlipidemic agents on C-reactive protein.
    Dandona P
    Mayo Clin Proc; 2008 Mar; 83(3):333-42. PubMed ID: 18316001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statin therapy to reduce stent thrombosis in acute myocardial infarction patients with elevated high-sensitivity C-reactive protein.
    Jeong HC; Ahn Y; Hong YJ; Kim JH; Jeong MH; Kim YJ; Chae SC; Cho MC;
    Int J Cardiol; 2013 Sep; 167(5):1848-53. PubMed ID: 22592028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-reactive protein levels and outcomes after statin therapy.
    Ridker PM; Cannon CP; Morrow D; Rifai N; Rose LM; McCabe CH; Pfeffer MA; Braunwald E;
    N Engl J Med; 2005 Jan; 352(1):20-8. PubMed ID: 15635109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
    Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
    Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-reactive protein (CRP)-lowering agents.
    Prasad K
    Cardiovasc Drug Rev; 2006; 24(1):33-50. PubMed ID: 16939632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or useful screening?
    Sellmayer A; Limmert T; Hoffmann U
    Int Angiol; 2003 Mar; 22(1):15-23. PubMed ID: 12771851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. I've heard that statins can can help lower C-reactive proteins (CRP) levels. I'm 65, but I don't take a statin because my cholesterol is low. Should I be concerned about CRP? I have a family history of heart disease.
    Heart Advis; 2011 Feb; 14(2):8. PubMed ID: 22957365
    [No Abstract]   [Full Text] [Related]  

  • 16. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?
    Yousuf O; Mohanty BD; Martin SS; Joshi PH; Blaha MJ; Nasir K; Blumenthal RS; Budoff MJ
    J Am Coll Cardiol; 2013 Jul; 62(5):397-408. PubMed ID: 23727085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein.
    Koenig W
    Int J Cardiol; 2005 Feb; 98(2):199-206. PubMed ID: 15686768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature.
    Patrick L; Uzick M
    Altern Med Rev; 2001 Jun; 6(3):248-71. PubMed ID: 11410071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [C-reactive protein in coronary plaques -- prevalence with acute coronary syndrome].
    Andrié R; Maylahn M; Braun P; Lüderitz B; Bauriedel G
    Z Kardiol; 2002 Nov; 91(11):913-20. PubMed ID: 12442194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [From lipid target values to the JUPITER study. Significance of achieving lipid levels specified by the guidelines and deficiencies in practice].
    Márk L; Katona A
    Orv Hetil; 2009 Nov; 150(44):2012-8. PubMed ID: 19861287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.